Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ahmet Sevindik

Set Alert for Articles By Ahmet Sevindik

Latest From Ahmet Sevindik

Turkish Decree Places New Caps On Drug Price Increases

In order to help curb the drugs bill, the Turkish Social Security Institution has decided to restrict the level of price increases that can be made on pharmaceutical products when the prices of those products are increased in reference or non-reference countries.

Pricing Debate Turkey

Inadequate And Counterproductive: Industry Criticizes Turkey’s Local Drug Production Policy

The general secretary of Turkey’s Association of Research based Pharmaceutical Companies (AIFD), Umit Dereli, tells the Pink Sheet why he thinks the government’s policy on local medicines production is wrong in terms of its scope, goal, and method.

Reimbursement Manufacturing

Turkey Poised To Stretch Consumer Health Market; Rigid On Ads, Access

Some 80 pharmaceutical and vitamin products already are available nonprescription in parts of Turkey, but a proposal in development for almost two years would be the country's first regulation for sales of consumer health care products.

Turkey Advertising, Marketing & Sales

Industry Lodges Legal Challenge To Turkey’s Local Drug Production Policy

Turkish drug industry association AIFD is demanding that the court cancels a government policy under which multinational companies are facing the threat of having their medicines removed from the reimbursement list unless they produce them locally.

Reimbursement Legal Issues

Turkey Finds Permanent Solution To Tamoxifen Shortage

The Turkish government plans to fix the country’s tamoxifen drug shortage problem by allowing by a local company to manufacture the product.

Market Access Pricing Debate

New Turkish Biosimilar Insulin Glargine Poses Challenge For Sanofi’s Lantus

Koçak Farma’s launch of a biosimilar version of Lantus could encourage Sanofi to invest in local production in Turkey, especially if the originator is at risk of being left off the reimbursement list.

Turkey Biosimilars
See All